KYTXHIGH SIGNALFINANCIAL10-K

KYTX shows severe cash burn acceleration with operating cash flow deteriorating 34.5% to -$153.7M while R&D expenses surged 18.9%, indicating unsustainable spending trajectory despite increased cash position.

The company is burning through cash at an alarming rate with operating losses expanding to -$161.3M, raising serious questions about runway duration and the need for additional financing. While cash increased to $124.1M, the accelerating burn rate of $153.7M annually suggests less than 12 months of runway at current spending levels, creating immediate liquidity pressure.

Comparing 2026-03-26 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

KYTX exhibits a classic biotech cash burn crisis with operating cash flow deteriorating 34.5% to -$153.7M while R&D expenses jumped 18.9% to $133.7M, driving net losses to -$161.3M. Despite cash increasing to $124.1M (likely from financing activities), the company faces severe runway constraints with current burn rates exceeding cash on hand annually. The 61.7% surge in total liabilities to $61.5M combined with declining stockholder equity signals mounting financial stress and imminent need for capital raises or strategic alternatives.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-99.8%
$2.2M$5K

Capex reduced 99.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
+61.7%
$38.1M$61.5M

Liabilities grew 61.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Cash Flow
Cash Flow
-34.5%
-$114.3M-$153.7M

Operating cash flow fell 34.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+28.4%
$96.6M$124.1M

Cash grew 28.4% — improving liquidity position supports investment and shareholder returns.

Net Income
P&L
-26.5%
-$127.5M-$161.3M

Net income declined 26.5% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-19.1%
-$142.6M-$169.8M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

R&D Expense
P&L
+18.9%
$112.5M$133.7M

R&D investment increased 18.9% — signals commitment to future product development, though near-term margin impact.

Stockholders Equity
Balance Sheet
-12.9%
$266.6M$232.3M

Equity decreased 12.9% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-27
ADDED
In some cases, you can identify forward-looking statements because they contain words such as may, will, should, expects, plans, anticipates, could, intends, target, projects, contemplates, believes, estimates, predicts, potential or continue or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions, but the absence of these words does not mean that a statement is not forward-looking.
The content of these third-party sources, except to the extent specifically set forth in this Annual Report on Form 10-K, does not constitute a portion of this Annual Report on Form 10-K and is not incorporated herein.
Although we are responsible for all of the disclosure contained in this Annual Report on Form 10-K and we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.
You are cautioned not to give undue weight to any such information, projections and estimates.
Overview We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases.
+7 more — sign up free →
REMOVED
In some cases, you can identify forward-looking statements because they contain words such as may, will, should, expects, plans, anticipates, could, intends, target, projects, contemplates, believes, estimates, predicts, potential or continue or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions.
While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.
In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in Part I, Item 1A of this Annual Report on Form 10-K titled Risk Factors and elsewhere in this Annual Report on Form 10-K.
Overview We are a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases.
Our approach is supported by our breadth of experience treating patients with our lead product candidate, KYV-101, across more than 15 autoimmune disease indications.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →